# A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune Checkpoint Inhibitors for All Comers of Intention-to-treat Patients With Hepatocellular Carcinoma Beyond UCSF Criteria Before Liver Transplantation

> **NCT07310836** · — · NOT_YET_RECRUITING · sponsor: **Ningbo Medical Center Lihuili Hospital** · enrollment: 300 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- Liver Transplantation

## Interventions

- **COMBINATION_PRODUCT:** Locoregional Therapy (LRT) + Systemic Drug Therapy

## Key facts

- **NCT ID:** NCT07310836
- **Lead sponsor:** Ningbo Medical Center Lihuili Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-20
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-03-31
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2025-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07310836

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07310836, "A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune Checkpoint Inhibitors for All Comers of Intention-to-treat Patients With Hepatocellular Carcinoma Beyond UCSF Criteria Before Liver Transplantation". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07310836. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*